2024-520200-26-00
Not yet recruiting
Phase 2
LUSPARA - A basket phase II clinical trial evaluating Luspatercept in patients affected with rare inherited anemias
Eurobloodnet Association6 sites in 2 countries45 target enrollmentStarted: October 24, 2025Last updated:
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Eurobloodnet Association
- Enrollment
- 45
- Locations
- 6
- Primary Endpoint
- the proportion of patients who achieve an erythroid response, defined as a reduction in the transfusion burden of at least 33% from baseline (the 12-week period before the first dose of luspatercept) during 12 weeks plus a reduction of at least 2 red cell units over this 12-week interval.
Overview
Brief Summary
To evaluate in patients with rare anemias, the effect of luspatercept on erythroid response at 12 weeks, ie reduction of transfusion burden which include either transfusion independence or significant reduction in the transfusion burden or increase in hemoglobin level as reported in thalassemia patients [4, 6]. The erythroid response at 12 weeks will be evaluated in each patient groups (CSA, CDA, NTD-DBA).
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patient affected with a rare constitutional anemia including. : ✔constitutional non syndromic sideroblastic anemia (CSA) including those due to germline mutation in ALAS2, SLC25A38, SLC19A2, GLRX5, HSPA9 and also more rare cases with other mutations. . Patients without genetic diagnosis (currently up to 30% of CSa patients may be included after approval of PI and geneticists ✔constitutional dyserythropïetic anemias CDA (type I and II) Diamond-Blackfan anemia not requiring regular transfusion support (NTD-DBA) (therapeutic independence or with continuous steroid therapy); 2 subgroups should be considered: RPS19 versus other genetic subgroups (mainly RPL5, RPL11 and RPS26 variants). Inclusions will be considered in order to have at least 3 patients in each subgroup before to expand inclusions
- •Male subjects must: Have agreed to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (eg, polyurethane), during sexual contact with a pregnant female or a FCBP while participating in the study, during dose interruptions, and for at least 12 weeks following IP discontinuation, even if he had undergone a successful vasectomy
- •For diseases of the three subtypes (CSA, CDA, and DBA-NTD), diagnosis must be supported genetically by presence of ACMG class 4 or 5 variant(s).
- •Age ≥18 years at the first screening
- •For CSA and CDA, both Transfusion dependent (TD) patients and Non Transfusion dependent (TD) patients may be included: ✔TD patients: transfusion-dependency definition is: 6 to 20 units of packed red cells within previous 24 weeks with no transfusion-free period of > 56 days (except for DBA patients for whom transfusion dependency is a factor of exclusion) ✔NTD patients: patients must have significant anemia e.g. hemoglobin < 10.5 gr/dl (average of at least 2 Hb measurements separated by a minimum of 7 days during screening period) occasional transfusion aloowed if ≤ 5 red-cell units per 24 weeks and red blood cell transfusion free > 8 weeks before inclusion
- •Adequate renal function, defined by creatinine less than 1.5 times the upper limit of normal, creatinine clearance ≥ 30 mL/min (MDRD formula).
- •Adequate liver function, defined by transaminases and gamma-glutamyl transferase less than 1.5 times the upper limit of normal.
- •ECOG performance status 0-2 at the time of screening.
- •Be willing and able to give written informed consent and to comply to all study procedures for the duration of the study.
- •A FCBP (female of childbearing potential) for this study was defined as a sexually mature woman who: (1) had not undergone a hysterectomy or bilateral oophorectomy; or (2) had not been naturally postmenopausal (amenorrhea following cancer therapy did not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). A FCBP participating in the study must: oHave had 2 negative pregnancy tests as verified by the investigator prior to starting the Investigational Product (IP) (unless the screening pregnancy test was done within 72 hours of Cycle 1 Day 1). She must have had agreed to ongoing a monthly pregnancy testing during the course of the study and after EOT oIf sexually active, agreed to have used, and been able to comply with, highly effective contraception** without interruption, 5 weeks prior to starting IP, during treatment with IP (including dose interruptions), and for 12 weeks after discontinuation of IP. ** Highly effective contraception was defined in this protocol as the following (information also appeared in the ICF): Hormonal contraception (eg, birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device, tubal ligation (tying your tubes), or a partner with a vasectomy
Exclusion Criteria
- •DBA patients with transfusion dependency or DBA patients with non RPS19, RPS26, RPL5 or RPL11 genotype or without gene identification
- •Known HIV infection or active hepatitis B or C.
- •Women who are or could become pregnant or who are currently breastfeeding.
- •Any medical or psychiatric contraindication that would prevent the patient from understanding and signing the informed consent form.
- •Patient eligible at short or medium term for allogeneic stem cell transplantation.
- •Known allergies to luspatercept or any of its excipients
- •No affiliation to a health insurance system
- •For men and women of reproductive potential: unwillingness to be abstinent or use double anticonception during the trial period.
- •Persons deprived of liberty by judicial or administrative decision
- •Persons subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
Outcomes
Primary Outcomes
the proportion of patients who achieve an erythroid response, defined as a reduction in the transfusion burden of at least 33% from baseline (the 12-week period before the first dose of luspatercept) during 12 weeks plus a reduction of at least 2 red cell units over this 12-week interval.
the proportion of patients who achieve an erythroid response, defined as a reduction in the transfusion burden of at least 33% from baseline (the 12-week period before the first dose of luspatercept) during 12 weeks plus a reduction of at least 2 red cell units over this 12-week interval.
The proportion of patients with a mean hemoglobin concentration increase of 1.0 g/dL or higher from baseline over a continuous 12-week interval in the absence of red blood cell transfusions
The proportion of patients with a mean hemoglobin concentration increase of 1.0 g/dL or higher from baseline over a continuous 12-week interval in the absence of red blood cell transfusions
Secondary Outcomes
- Proportion of patients with a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval,
- Proportion of patients with a reduction in the transfusion burden of at least 50% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval,
- Proportion of patients with a reduction in the transfusion burden of at least 33% from baseline during weeks 37 through 48 plus a reduction of at least 2 red-cell units over this 12-week interval
- Proportion of patients with a reduction in the transfusion burden of at least 50% from baseline during weeks 37 through 48 plus a reduction of at least 2 red-cell units over this 12-week interval
- Mean change from baseline in the transfusion burden during weeks 13 through 24 and during weeks 37 through 48
Investigators
Thierry LEBLANC
Scientific
Eurobloodnet Association
Study Sites (6)
Loading locations...
Similar Trials
Active, not recruiting
Phase 3
一项在≥18 岁温抗体型自身免疫性溶血性贫血参与者中比较口服 rilzabrutinib 与安慰剂的疗效、安全性和药代动力学的研究CTR2025293015
Recruiting
Phase 2
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaAnemiaNCT05664737Bristol-Myers Squibb189
Active, not recruiting
Phase 3
A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on concomitant JAK2 inhibitor therapy and who require red blood cell transfusions2023-507890-17-00Celgene Corp.150
Recruiting
Phase 2
A phase II, open-label, single arm study to evaluate the efficacy of
Luspatercept in Erythropoiesis-stimulating agent naive lower-risk
MDS patients with or without ring sideroblasts who do not require
RBC transfusions2024-516438-36-00Universitaet Leipzig30
Recruiting
Phase 2
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS)2022-502743-35-00Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.52